Pioglitazone therapy has been shown to prevent recurrent stroke in patients with insulin resistance and previous stroke but carries an increased risk of bone fracture. Anthracycline chemotherapy reduces the risk of breast cancer recurrence but carries a risk of cardiotoxicity. We hypothesized that risk modeling can help identify subgroups of patients that vary substantially in their benefit-harm trade-offs with these therapies.
